StreetInsider.com News Articles

Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum

Tue, 02 Jun 2026 09:00:00 -0400

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (OTCQB: ALUR), a pioneer in metabolically healthy weight loss, today announced successful early traction in the launch of the Allurion Program in the United States, marked by strong clinical outcomes, rapid account growth, high re-order rates, and performance exceeding internal expectations.

First shipments of the Allurion Smart Capsule were completed in April, with the first U.S. patients treated that same month. Early clinical outcomes have been highly encouraging, with patients losing between 8–11% of their total body weight in just the first four weeks, reinforcing the program’s potential to deliver rapid, meaningful

Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum

Tue, 02 Jun 2026 09:00:00 -0400

Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum

Tue, 02 Jun 2026 09:00:00 -0400

Allurion Announces Strong Start to U.S. Launch with Exceptional Early Outcomes and Growth Momentum

Tue, 02 Jun 2026 09:00:00 -0400

Form 8-K ALLURION TECHNOLOGIES, For: May 20

Wed, 27 May 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260527/26558528.html

Form 8-K ALLURION TECHNOLOGIES, For: May 20

Wed, 27 May 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260527/26558528.html

Form 10-Q ALLURION TECHNOLOGIES, For: Mar 31

Fri, 15 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260515/26506601.html

Form 10-Q ALLURION TECHNOLOGIES, For: Mar 31

Fri, 15 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260515/26506601.html

Allurion Treats First Commercial Patients in the United States, Marking Major Milestone

Mon, 20 Apr 2026 08:30:00 -0400

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced the successful commercial treatment of its first patients in the United States—an inflection point that formally launches the company into the world’s largest and most dynamic obesity market.

Allurion is seeing growing demand from patients who have discontinued GLP-1 therapy due to side effects, long-term commitment concerns, or weight regain following discontinuation. These early patient profiles reinforce Allurion’s positioning as a compelling, non-surgical, non-pharmaceutical option that delivers fast weight loss results within the rapidly evolving obesity treatment landscape.

Early feedback from trained

Allurion Treats First Commercial Patients in the United States, Marking Major Milestone

Mon, 20 Apr 2026 08:30:00 -0400

Early feedback from trained

Allurion Treats First Commercial Patients in the United States, Marking Major Milestone

Mon, 20 Apr 2026 08:30:00 -0400

Early feedback from trained

Allurion Treats First Commercial Patients in the United States, Marking Major Milestone

Mon, 20 Apr 2026 08:30:00 -0400

Early feedback from trained

Form 10-K ALLURION TECHNOLOGIES, For: Dec 31

Mon, 30 Mar 2026 08:31:00 -0400

http://archive.fast-edgar.com/20260330/AI22H22DZW2RT9Z222262ZYRVUJJYZ223282

Filed on: March 30, 2026

Form 10-K ALLURION TECHNOLOGIES, For: Dec 31

Mon, 30 Mar 2026 08:31:00 -0400

http://archive.fast-edgar.com/20260330/AI22H22DZW2RT9Z222262ZYRVUJJYZ223282

Filed on: March 30, 2026

Form 8-K ALLURION TECHNOLOGIES, For: Mar 06

Thu, 12 Mar 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260312/26154480.html

Form 8-K ALLURION TECHNOLOGIES, For: Mar 06

Thu, 12 Mar 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260312/26154480.html

Allurion appeals NYSE delisting, cites FDA approval in compliance plan

Thu, 12 Mar 2026 16:16:37 -0400

Allurion Technologies Inc. (OTCID: ALUR) has appealed the New York Stock Exchange's decision to initiate delisting proceedings against the company's securities, according to a company statement.

The NYSE moved to delist Allurion under Section 802.01B of its Listed Company Manual, which requires listed companies to maintain an average global market capitalization of at least $15 million over a consecutive 30 trading day period.

Allurion received FDA approval for its Gastric Balloon System on February 20, 2026, and has developed a plan to regain NYSE compliance or seek listing on NYSE American. The company has shared this plan with the NYSE and is

Allurion Advances Plan to Regain Listing Compliance

Thu, 12 Mar 2026 16:15:00 -0400

Files appeal to NYSE on decision to initiate delisting proceedings

Company’s recent FDA approval catalyzes plan to regain compliance with the continued listing requirements of NYSE or initial listing requirements of the NYSE American

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (the “Company”) (OTCID: ALUR), a pioneer in metabolically healthy weight loss, announced today that it has appealed the decision by the New York Stock Exchange (the “NYSE”) to initiate delisting proceedings against Allurion’s securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual, which requires listed companies to maintain an average global market capitalization over a

Allurion Advances Plan to Regain Listing Compliance

Thu, 12 Mar 2026 16:15:00 -0400

Files appeal to NYSE on decision to initiate delisting proceedings

Company’s recent FDA approval catalyzes plan to regain compliance with the continued listing requirements of NYSE or initial listing requirements of the NYSE American

Allurion Advances Plan to Regain Listing Compliance

Thu, 12 Mar 2026 16:15:00 -0400

Files appeal to NYSE on decision to initiate delisting proceedings

Company’s recent FDA approval catalyzes plan to regain compliance with the continued listing requirements of NYSE or initial listing requirements of the NYSE American

Allurion Advances Plan to Regain Listing Compliance

Thu, 12 Mar 2026 16:15:00 -0400

Files appeal to NYSE on decision to initiate delisting proceedings

Company’s recent FDA approval catalyzes plan to regain compliance with the continued listing requirements of NYSE or initial listing requirements of the NYSE American

Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

Wed, 11 Mar 2026 09:00:00 -0400

First shipments expected in April

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced that it has officially begun training and on‑boarding partner accounts across the United States, including large academic medical centers and private practices. The company has begun manufacturing FDA-approved product and expects to begin shipping in April. This milestone represents a pivotal step in the company’s commercial expansion into the world’s largest markets for obesity treatment, where an estimated 20 million Americans have already started and stopped a GLP-1 medication, which presents an immediately accessible target

Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

Wed, 11 Mar 2026 09:00:00 -0400

First shipments expected in April

Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

Wed, 11 Mar 2026 09:00:00 -0400

First shipments expected in April

Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

Wed, 11 Mar 2026 09:00:00 -0400

First shipments expected in April